Administration of ciprofloxacin through a nasogastric tube in pediatric oncology and stem cell transplantation patients.
Tiene BautersFranky BuylePetra SchelstraeteCatharina DhoogePublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Pediatric oncology and hematopoietic stem cell transplantation patients are facing many gastrointestinal side effects of chemotherapy, including nausea, vomiting, mucositis, and diarrhea. International guidelines advise early enteral tube feeding as the first option of nutritional support in children undergoing myeloablative hematopoietic stem cell transplantation. When using enteral feeding tubes for nutritional purposes as well as drug administration, some pharmaceutical, nursing, and technical issues have to be taken into account. Ciprofloxacin is a fluoroquinolone, widely used because of its broad spectrum antimicrobial activity and favorable pharmacokinetic properties. However, its co-administration with polyvalent cations (as present in enteral feeding) makes the absorption of ciprofloxacin more difficult and may alter the pharmacokinetic parameters. Literature data are conflicting on how long the enteral feeding should be discontinued for patients receiving ciprofloxacin via an enteral feeding tube, ranging from 2 h before to 6 h after the administration of ciprofloxacin. Our research question was guided by challenges and concerns of nurses about the delay time between ciprofloxacin administration and restart of the enteral feeding without compromising the nutritional intake of the children. Our guideline was adapted, nurses were instructed accordingly, and patient leaflets with correct information were created.
Keyphrases
- stem cell transplantation
- pseudomonas aeruginosa
- end stage renal disease
- chronic kidney disease
- ejection fraction
- mental health
- newly diagnosed
- young adults
- high dose
- prognostic factors
- systematic review
- acute myeloid leukemia
- peritoneal dialysis
- cystic fibrosis
- squamous cell carcinoma
- chemotherapy induced
- low dose
- body mass index
- artificial intelligence
- quality improvement
- ionic liquid
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- health information